Investigational drug study for Treatment of Non-Small Cell Lung Cancer

Trial ID:
IRB-18-7138
Michael P. Kosty, M.D.
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.

Inclusion Criteria

Patients must:

  • Be 18 years of age or older
    Have resectable Stage II, IIA, or Select IIIB Non-small cell lung cancer

Exclusion Criteria

Patients must not:

  • Have had any prior therapy for lung cancer, including chemotherapy or radiotherapy
    Have had any major surgical procedure within 28 days prior to starting study treatment
    Have any significant heart disease
    Have a history of cancer other than lung cancer within the last 5 years
    Be pregnant or nursing

Additional Info

Atezolizumab is an investigational immunotherapy drug that is designed to work with the body's own immune system. It may help to activate the immune response and stop a protein called PD-L1 from preventing the body's immune system from fighting cancer.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org

Why isn't this trial accepting new patients?

The trial may have a limited enrollment number, reached its maximum, or come to the end of its enrollment period. View trials that are recruiting

How else can Scripps help me?

We have a broad range of physician expertise and specialized medical services available. You can find a doctor online, call 1-800-SCRIPPS (1-800-727-4777) for personal help, or see related Scripps services.

How can I find trials that are accepting new participants?

For more information, see a list of trials that are recruiting, or call the clinical research office at 858-648-6402 for help.